Search - tctmd.com

Displaying 321 - 340 of 428

Sort: Relevancy | Date

News Industry News

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

November 29, 2015

News Daily News

Good News, Bad News Week for Watchman LAA Occluder

Shelley Wood

November 12, 2015

News Conference News AHA 2015

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Yael L. Maxwell

November 10, 2015

News Daily News

NEJM Apoya a Robert Califf como Comisionado de la FDA

L.A. McKeown

October 30, 2015

News Daily News

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

Todd Neale

October 26, 2015

News Daily News

Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones

Todd Neale

October 26, 2015

News Opinion Editor's Corner TCT 2015

My Takeaways From TCT 2015

Shelley Wood

October 20, 2015

News Industry News

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

September 09, 2015

News Conference News ESC 2015

NSAIDs Plus Anticoagulants a Bad Combination

Caitlin E. Cox

September 01, 2015

News Daily News

El Tratamiento Triple No ofrece Beneficio Trombótico y Sí Más Hemorragias en Pacientes Ancianos con FA sometidos a PCI

August 04, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Daily News

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

L.A. McKeown

July 13, 2015

News Daily News

Acute MI Arising From Coronary Embolism Rare, Often Tied to A-fib

L.A. McKeown

July 08, 2015

News Daily News

Los IAM secundarios a Embolismos Coronarios son Raros y Suelen Asociarse a la FA

L.A. McKeown

July 08, 2015

News Daily News

Un Comunicado sobre el Cierre del AAI Señala los Puntos clave en este Campo

July 02, 2015

News Daily News

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

June 25, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Daily News

RE-VERSE AD: El Antídoto de Dabigatran, Seguro y Eficaz en un Análisis Provisional

June 25, 2015

News Industry News

Patients Undergoing Catheter Ablation Presented at Heart Rhythm 2015

May 15, 2015

News Daily News

La Trombosis Valvular Post-TAVR podría ser Más Habitual de lo que se Creía

L.A. McKeown

May 06, 2015

Advertisement

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

Good News, Bad News Week for Watchman LAA Occluder

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

NEJM Apoya a Robert Califf como Comisionado de la FDA

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones

My Takeaways From TCT 2015

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

NSAIDs Plus Anticoagulants a Bad Combination

El Tratamiento Triple No ofrece Beneficio Trombótico y Sí Más Hemorragias en Pacientes Ancianos con FA sometidos a PCI

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

Acute MI Arising From Coronary Embolism Rare, Often Tied to A-fib

Los IAM secundarios a Embolismos Coronarios son Raros y Suelen Asociarse a la FA

Un Comunicado sobre el Cierre del AAI Señala los Puntos clave en este Campo

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

RE-VERSE AD: El Antídoto de Dabigatran, Seguro y Eficaz en un Análisis Provisional

Patients Undergoing Catheter Ablation Presented at Heart Rhythm 2015

La Trombosis Valvular Post-TAVR podría ser Más Habitual de lo que se Creía

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content